Peptides and compounds that bind to a receptor

Details Peptides and compounds that bind to a receptor Peptides and compounds that bind to a receptor

2004-08-13

2009-08-18

Tsang, Cecilia (Department: 1654)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C514S002600, C514S013800, C514S014800, C514S015800, C514S017400, C530S300000, C530S324000, C530S325000, C530S326000, C530S327000

Reexamination Certificate

active

07576056

ABSTRACT:
Peptide compounds that bind to and activate the thrombopoietin receptor (c-mpl or TPO-R) or otherwise act as a TPO agonist are disclosed.

REFERENCES:
patent: 5141851 (1992-08-01), Brown et al.
patent: 5143854 (1992-09-01), Pirrung et al.
patent: 5270170 (1993-12-01), Schatz et al.
patent: 5326558 (1994-07-01), Turner et al.
patent: 5338665 (1994-08-01), Schatz et al.
patent: 5358934 (1994-10-01), Borovsky et al.
patent: 5384331 (1995-01-01), Kogan et al.
patent: 5411942 (1995-05-01), Widmer et al.
patent: 5869451 (1999-02-01), Dower et al.
patent: 5932546 (1999-08-01), Barrett et al.
patent: 6060052 (2000-05-01), Murray et al.
patent: 6083913 (2000-07-01), Dower et al.
patent: 6251864 (2001-06-01), Dower et al.
patent: 0 668 352 (1995-02-01), None
patent: 0 675 201 (1995-03-01), None
patent: 0 450 715 (1995-12-01), None
patent: 0 690 127 (1996-01-01), None
patent: 0 783 003 (2006-11-01), None
patent: 2 285 446 (1995-07-01), None
patent: WO 90/15070 (1990-12-01), None
patent: WO 91/07988 (1991-06-01), None
patent: WO 91/08752 (1991-06-01), None
patent: WO 93/25221 (1993-12-01), None
patent: WO 95/11922 (1995-05-01), None
patent: WO 95/18858 (1995-07-01), None
patent: WO 95/21626 (1995-08-01), None
patent: WO 95/21919 (1995-08-01), None
patent: WO 95/21920 (1995-08-01), None
patent: WO 95/28907 (1995-11-01), None
patent: WO 96/17062 (1996-06-01), None
patent: WO 96/17067 (1996-06-01), None
patent: WO 96/34016 (1996-10-01), None
patent: WO 96/40750 (1996-12-01), None
patent: WO 98/25965 (1998-06-01), None
patent: WO 01/21180 (2001-03-01), None
patent: WO 02/078612 (2002-10-01), None
patent: WO 2004/026332 (2004-04-01), None
patent: WO 2005/023834 (2005-03-01), None
De Serres M, Yeager RL, Dillberger JE, Lalonde G, Gardner GH, Rubens CA, Simkins AH, Sailstad JM, McNulty MJ, Woolley JL, Pharmacokinetics and Hematological Effects of the PEGylated Thrombopoietin Peptide Mimetic GW395058 in Rats and Monkeys After Intravenous or SUbcutaneous Administration, Stem Cells, 1999, 17: 316-326.
International Search Report dated Mar. 15, 2007 for corresponding Appln. No. PCT/US2006/030359.
Case B.C., et al.: “The pharmacokinetics and pharmacodynamics of GW395058, a peptide agonist of the thrombopoietin receptor, in the dog, a large-animal model of chemotherapy-induced thrombocytopenia” Stem Cells (Dayton Ohio) 2000 vol. 18, No. 5, pp. 360-365, XP002421199.
De Serres M. et al.: “Immunogenicity of thrombopoietin mimetic peptide GW395058 in BALB7c mice and New Zealand white rabbits” evaluation of the potential for thrombopoietin neutralizing antibody production in man Stem Cells, Alphamed Press, Dayton, OH, US, vol. 17, 1999, pp. 203-209, XP002230261.
Kaushansky K: “Hematopoietic growth factor mimetics” Annals of the New York Academy of Sciences Jun. 2001, vol. 938, pp. 131-138, XP002421201.
Renschler, M: “Synthetic peptide ligands of the antigen binding receptor induce programmed cell death in a human B-cell lymphoma”, Immunology, vol. 91, pp. 3623-3627 (1994).
Singer S.C. et al: “Pegylated Thrombopoietin (TPO)-mimetic Peptides Bind Human to TPO receptor causing proliferation and maturation of megakaryocytes in vitro” Blood, vol. 92 No. 10, Nov. 15, 1998, p. 568A, XP009079489 & 40thAnnual Meeting of the American Society of Hematology; Miami Beach, Florida, USA, Dec. 4-8, 1998.
Wrighton, N. et al: “Small Peptide Mimetics of Erthropoietin”, Blood, vol. 88, No. 10 (Supp. 1), pp. 543-545 (1996).
Ballmaier et al. “c-mplmutations are the cause of congenital amegakaryocytic thrombocytopenia”, Blood, vol. 97, No. 1, pp. 139-146 (2001).
Barker et al. “Cyclic RGD Peptide Analogues as Antiplatelet Antithrombotics”, J. Med. Chem. vol. 35, pp. 2040-2048 (1992).
Bartley et al. “Identification and Cloning of a Megakaryocyte Growth and Development Factor That Is a Ligand for the Cytokine Receptor Mpl”, Cell, vol. 77, pp. 1117-1124 (1994).
Basser et al., “Randomized, Blinded, Placebo-Controlled Phase I Trail of Pegylated Recombinant Human Megakaryocyte Growth and Development Factor With Fiilgrastim After Dose-Intensive Chemotherapy in Patients With Advanced Cancer”, Blood, vol. 89, No. 9, pp. 3118-3128 (1997).
Bazan, “Structural design and molecular evolution of a cytokine receptor superfamily”, Proc Natl. Acad. Sci. USA, vol. 87, pp. 6934-6938 (1990).
Berger et al. “A New Method for the Synthesis of Optically Active α-Amino Acids and Their NαDerivativesviaAcylamino Malonates”, J. Org. Chem., vol. 38, No. 3, pp. 457-460 (1973).
Caras et al. “Signal Peptide for Protein Secretion Directing Glycophospholipid Membrane Anchor Attachment”, Science, vol. 243, pp. 1196-1198 (1989).
Cwirla et al. “Peptides on Phage: A Vast Library of Peptides for Identifying Ligands”, Proc. Natl. Acad. Sci. USA, vol. 87, pp. 6378-6382 (1990).
Daumas et al. “Gramicidin A analogs: influence of the substitution of the tryptophans by naphthylalanines”, Biochimie, vol. 71, pp. 77-81 (1989).
de Sauvage et al. “Stimulation of megakaryocytopoiesis and thrombopoiesis by the c-Mpl ligand”, Nature, vol. 369, pp. 533-538 (1994).
Dexter et al. “Growth of Factor-Dependent Hemopoietic Precursor Cell Lines”, J. Exp. Med., vol. 152, pp. 1036-1047 (1980).
Dower et al. “The Search for Molecular Diversity (II): Recombinant and Synthetic Randomnized Peptide Libraries”, Annual Reports in Medicinal Chemistry, vol. 26, pp. 271-280 (1991).
Dower et al. “High efficiency transformation ofE.coliby high voltage electroporation”, Nucleic Acids Research, vol. 16, No. 13, pp. 6127-6145 (1988).
Evans et al. “Design of Nonpeptidal Ligands for a Peptide Receptor: Cholecystokinin Antagonists”, J. Med. Chem, vol. 30, pp. 1229-1239 (1987).
Fauchére “Elements for the Rational Design of Peptide Drugs”, Advances in Drug Research, vol. 15, pp. 29-69 (1986).
Fodor et al. “Light-Directed, Spatially Addressable Parallel Chemical Synthesis”, Science, vol. 251, pp. 767-773 (1991).
Fox et al. “Thrombopoietin expands hematopoietic stem cells after transplantation”, The Journal of Clincal Investigation, vol. 110, No. 3, pp. 389-394 (2002).
Gante “Peptidomimetics-Tailored Enzyme Inhibitors”, Angen. Chem. Int. Ed. Engl., vol. 33, pp. 1699-1720 (1994).
Harker “Kinetics of Thrombopoiesis”, The Journal of Clinical Investigation, vol. 47, pp. 458-465 (1968).
Kato et al., “Purification and Characterization of Thrombopoietin1”, J. Biochem. vol. 118, No. 1, pp. 229-236 (1995).
Kaushansky et al., “Promotion of megakaryocyte progenitor expansion and differentation by the c-Mpl ligand thrombopoietin”, Nature, vol. 369, pp. 568-571 (1994).
Kaushansky et al., “Thrombopoietin Expands Erythroid Progenitors, Increases Red Cell Production, and Enhances Erythroid Recovery after Myelosuppressive Therapy”, J. Clin. Invest., vol. 96, pp. 1683-1687 (1995).
Kaushansky et al., “Thrombopoietin expands erythroid, granulocyte-macrophage, and megakaryocytic progenitor cells in normal and myelosuppressed mice”, Experimental Hematology, vol. 24, pp. 265-269 (1996).
Kimura et al. “Hematopoietic stem cell deficiencies in mice lacking c-Mpl, the receptor for thrombopoietin”, Proc. Natl. Acad. Sci. USA, vol. 95, pp. 1195-1200 (1998).
Kojima et al. “Molecular Cloning and Expression of Megakaryocyte Potentiating Factor cDNA*”, The Journal of Biological Chemistry, vol. 270, No. 37, pp. 21984-21990 (1995).
Ku et al. “Thrombopoietin, the Ligand for the Mpl Receptor, Synergizes With Steel Factor and Other Early Acting Cytokines in Supporting Proliferation of Primitive Hematopoietic Progenitors of Mice”, Blood, vol. 87, No. 11, pp. 4544-4551 (1996).
Kuter et al. “The purification of megapoietin: A physiological regulator of megakaryocyte growth and platelet

Affiliated with

Also associated with

Rating

Peptides and compounds that bind to a receptor does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Peptides and compounds that bind to a receptor, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Peptides and compounds that bind to a receptor will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4132386